What drove the 12 Feb 2026 rise in CYAD.BR stock?

The rise came from heavy volume of **469,178** shares and renewed interest in Celyad Oncology SA’s CAR-T pipeline. Short-term trading flows and speculative buying amplified the move, while no broad sector catalyst was evident.

What is Meyka AI’s price forecast for CYAD.BR stock?

Meyka AI's forecast model projects a **monthly target of €0.31** and a **yearly model of €0.20**. Versus the close **€0.27**, those imply **+13.97%** and **-26.44%**, respectively. Forecasts are model-based and not guarantees.

How risky is investing in CYAD.BR stock now?

CYAD.BR stock is high risk due to negative earnings (EPS **-0.89**), tight liquidity (current ratio **0.66**), and biotech trial uncertainty. Large intraday volume spikes increase volatility. Use position limits and await clinical or cash-flow clarity.

Where can I verify company information and filings for CYAD.BR stock?

Company details are available on Celyad Oncology SA’s website and public filings. For corporate data and quotes consult the issuer site [source](https://www.celyad.com) and market data providers [source](https://financialmodelingprep.com).

EU Stocks

CYAD.BR Celyad Oncology EURONEXT +23.08% 12 Feb 2026: volume spike hints momentum

ByDanny Kontos February 13, 2026February 13, 2026

CYAD.BR stock jumped 23.08% to €0.27 at market close on 12 Feb 2026, driven by a large volume spike of 469,178 shares versus an average of 20,697. The move pushed the intraday range to €0.26–€0.32 and cut the 50-day average gap, with the 50-day at €0.18 and the 200-day at €0.29. Traders priced fresh optimism around Celyad Oncology SA’s clinical-stage CAR-T programs, while volatility surged: relative volume hit 22.67x. We examine what moved the price, the company’s financials, technicals, a Meyka AI grade, and model forecasts for investors and traders.